Tag: FOR

New York, New York, June 08, 2026 (GLOBE NEWSWIRE) -- Snow Rothschild Acquisition Corp. (NASDAQ: ISNRU) (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. Each unit issued in the offering consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust acting as trustee.  The Company’s units are expected to be listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ISNRU” and are expected to begin trading on June 9, 2026. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “ISNR” and “ISNRW,” respectively. The closing of the offering is anticipated to take place on or about June 10, 2026, subject to customary closing conditions.

Vancouver, BC, June 08, 2026 (GLOBE NEWSWIRE) -- SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (FSE: MJ5), a pioneer in autonomous AI sales technology, today announced that, further to the Company’s news release dated March 31, 2026, regarding the Company’s consulting agreement with Green Times Consulting Ltd. (“Green Times”) dated April 1, 2026 (the “Consulting Agreement”), the Company issued the second and final tranche of 87,064 common shares to Green Times at a price of $0.844 per share as payment for the consulting services provided to the Company for the period May 1 - May 31, 2026.  The payment shares are subject to a four-month resale hold period ending October 9, 2026. 

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.